Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.20.4
Earnings (Loss) Per Common Share (Tables)
 6 Months Ended
Dec. 31, 2020
Earnings (Loss) Per Common Share  
Schedule of Earnings (loss) Per Share, Basic and Diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months ended

 

Six Months ended

 

 

December 31, 

 

December 31, 

 

    

2020

    

2019

    

2020

    

2019

Basic and diluted numerator:

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

  

 

 

  

 

 

  

 

 

  

Net loss attributable to iBio, Inc.

 

$

(8,129)

 

$

(3,762)

 

$

(15,662)

 

$

(8,225)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

 

(65)

 

 

(65)

 

 

(131)

 

 

(131)

Deemed dividends – down round of Series A  Preferred and Series B Preferred

 

 

 —

 

 

(21,560)

 

 

 —

 

 

(21,560)

Net loss available to iBio, Inc. stockholders

 

$

(8,194)

 

$

(25,387)

 

$

(15,793)

 

$

(29,916)

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

188,087

 

 

36,917

 

 

175,264

 

 

29,420

 

 

 

 

 

 

 

 

 

 

 

 

 

Per share amount

 

$

(0.04)

 

$

(0.69)

 

$

(0.09)

 

$

(1.02)

 

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

 

 

 

 

 

 

 

December 31, 

 

    

2020

    

2019

 

 

(in thousands)

Stock options

 

4,251

 

1,259

Restricted stock units

 

349

 

 —

Series A Warrants

 

 —

 

21,930

Series B Warrants

 

 —

 

24,930

Series A Preferred

 

 —

 

60

Series B Preferred

 

 —

 

28,925

Series C Preferred

 

 —

 

100

Shares excluded from the calculation of diluted loss per share

 

4,600

 

77,204